STOCK TITAN

Bio-Rad Laboratories, Inc. - BIO STOCK NEWS

Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.

Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.

Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.

The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.

Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.

Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.

One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.

With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.

Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced it will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) on the same day to discuss the results. Investors can participate by dialing 800-343-4849 (U.S.) or 203-518-9856 (outside U.S.) with the access code: BIORAD. A live webcast will be available on the company's website, and a replay will be accessible for up to a year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
conferences earnings
-
Rhea-AI Summary

Bio-Rad Laboratories has appointed Anette Engelhardt as Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Engelhardt joins from Cepheid, where she was a Senior Vice President and General Manager. At Cepheid, she managed emerging growth opportunities and led global R&D, strategy, and product management. She has significant experience in the diagnostics field, having held senior roles at bioMerieux and served as CEO of AB BIODISK. Andy Last, Bio-Rad’s Executive VP and COO, expressed confidence in Engelhardt's ability to drive the company's clinical diagnostics strategy and product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary

Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 10:30 AM ET (7:30 AM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
Rhea-AI Summary

Bio-Rad Laboratories, Inc. reported first-quarter 2024 financial results with total net sales of $610.8 million, a decrease of 9.8% compared to the same period in 2023. While Life Science segment sales dropped by 25.3%, Clinical Diagnostics segment sales increased by 4.7%. Net income for the quarter was $383.9 million, or $13.45 per share, compared to $69.0 million, or $2.32 per share, in 2023. Bio-Rad remains cautiously optimistic about a gradual biopharma market recovery and confident in their long-term strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
-
Rhea-AI Summary

Bio-Rad Laboratories, Inc. will have its COO and CFO participate in a fireside chat during the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be webcasted and available for replay on the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences
-
Rhea-AI Summary

Bio-Rad Laboratories, Inc. announced the promotion of James J. Barry to Executive Vice President and President of the Life Science Group, succeeding Dr. Simon May. Barry's extensive experience and leadership roles in quality systems and global manufacturing make him well-suited for the position. The CEO expressed confidence in Barry's ability to lead the global life science business, acknowledging May's contributions to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
management
Rhea-AI Summary
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its first quarter 2024 financial results on May 7, 2024. The conference call will take place at 2 PM Pacific Time. Investors can access the call through dial-in or a live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
conferences earnings
-
Rhea-AI Summary
Bio-Rad Laboratories, Inc. announces the retirement of Dr. Andrew Last, the Executive Vice President and COO, by early September 2024. Dr. Last, with over 30 years of experience, joined in 2019 and played a vital role in the company's transformational objectives and navigating macroeconomic challenges. The company is conducting a search for his successor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
none
-
Rhea-AI Summary
Bio-Rad Laboratories, Inc. appoints Roop K. Lakkaraju as the new Executive Vice President and Chief Financial Officer, bringing extensive experience in financial management and operations. Lakkaraju's track record in mergers, acquisitions, and capital markets transactions will shape and execute Bio-Rad's financial strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
management
Rhea-AI Summary
Bio-Rad Laboratories, Inc. to participate in Citi's 2024 Unplugged Medtech and Life Sciences Access Day fireside chat event. The event will take place on February 29, 2024, at 2:30 PM Eastern Time. Investors can access the live webcast and replay on Bio-Rad's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences

FAQ

What does Bio-Rad Laboratories, Inc. specialize in?

Bio-Rad specializes in providing innovative tools and services for the life science research and clinical diagnostics markets.

When was Bio-Rad Laboratories founded?

Bio-Rad Laboratories was founded in 1952.

Where is Bio-Rad Laboratories headquartered?

Bio-Rad Laboratories is headquartered in Hercules, California.

What are the core business segments of Bio-Rad?

Bio-Rad's core business segments are Clinical Diagnostics and Life Sciences.

What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?

56% of Bio-Rad's sales come from the Clinical Diagnostics segment.

How many employees does Bio-Rad have?

Bio-Rad employs over 7,600 people.

What is Bio-Rad's involvement in the biopharmaceutical industry?

Bio-Rad develops and manufactures instruments and reagents used in biopharmaceutical production and owns 33% of Sartorius, a supplier specializing in biologics manufacturing technology.

What is Bio-Rad's market reach?

Bio-Rad serves over 100,000 research and industry customers worldwide with major markets in the Americas, Europe, Asia, and other regions.

What is the significance of Bio-Rad's ownership in Sartorius?

Bio-Rad's ownership in Sartorius enhances its biopharmaceutical offerings, particularly in single-use technology for biologics manufacturing.

How does Bio-Rad contribute to scientific research and development?

Bio-Rad advances scientific research and development by providing high-quality instruments, reagents, and test systems used in genomics, proteomics, drug discovery, food safety, and medical diagnostics.

Bio-Rad Laboratories, Inc.

NYSE:BIO

BIO Rankings

BIO Stock Data

8.61B
23.45M
15.2%
79.83%
3.04%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
HERCULES